Eliquis Tablet, Film Coated
Product Images NDC 71610-811

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Eliquis (NDC 71610-811). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 811 83)

FDA Label Image

Aphena (Aphena)

FDA Label Image

Apixaban Chemical Structure (Apixaban Struct)

FDA Label Image

Aristotle Forest Plot (Eliquis Clin Forest Fig5)

FDA Label Image

Aristotle Major Bleeding Forest Plot (Eliquis Forest Fig1)

FDA Label Image

Aristotle Kaplan-meier Curve (Eliquis Km Fig4)

FDA Label Image

Effect Of Coadministered Drugs On Pharmacokinetics Of Apixaban (Eliquis Pkplot Drugs Fig2)

Effect Of Coadministered Drugs On Pharmacokinetics Of Apixaban (Eliquis Pkplot Drugs Fig2)
This text provides information on the drug-drug interactions and the effect on pharmacokinetics with specific drugs acting as inhibitors or inducers of P-gp and CYP3A4 enzymes. It includes data on the fold change in PK (pharmacokinetics) and the corresponding 90% confidence intervals for drugs like Ketoconazole, Clarithromycin, Diltiazem, Naproxen, and Rifampin. The relative changes in AUC values are also noted for each drug interaction.*
FDA Label Image

O:\e-submissions\pbo\products\eliquis 202155\08. Pas Esrd Dosing\01. Orig Submission\source\eliquis-pkplot-pop-fig3.jpg (Eliquis Pkplot Pop Fig3)

O:\e-submissions\pbo\products\eliquis 202155\08. Pas Esrd Dosing\01. Orig Submission\source\eliquis-pkplot-pop-fig3.jpg (Eliquis Pkplot Pop Fig3)
This text provides information on population descriptions, PK fold change, and recommendations for dose adjustments based on different parameters such as age, body weight, renal impairment, and hepatic impairment. It outlines specific scenarios where dose adjustments may or may not be necessary for optimal treatment outcomes.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.